Table 5.

Hepatitis B virus (HBV) reactivation or HBV DNA reappearance in patients with HBV and hepatitis C virus (HCV) co-infection after direct-acting antiviral (DAA) treatment [70–78]

Authors (year) [references]	Total patients (n)	Observation periods (months post-EOT)	Patients with increases of HBV DNA greater than 1 log10 IU/mL or HBV DNA reappearance [n (%)]	Monthly incidence of HBV reactivation or HBV DNA reappearance (%/month)
HBsAg-positive patients
Gane et al. (2016) [70]	8	3	7 (87.5)	29.2
Doi et al. (2017) [71]	4	3	2 (50)	16.7
Kawagishi et al. (2017) [72]	4	3	2 (50)	16.7
Yeh et al. (2017) [73]	7	3	7 (100)e	33.3
Mucke et al. (2017) [74]	8	3	4 (50)b	16.7
Wang et al. (2017) [75]	10	3	3 (33.3)d	11.1
Tamori et al. (2018) [76]	12	3	3 (25)c	8.3
Liu et al. (2018) [77]	109	3	39 (35.8)a	13
Total	162	3	67 (41.4)	18.1 (8.33–33.3)
HBsAg-negative patients positive for anti-HBc antibody and/or anti-HBs antibody
Yeh et al. (2017) [73]	57	3	0 (0)	0
Wang et al. (2017) [75]	124	3	0 (0)	0
Doi et al. (2017) [71]	155	3	3 (1.9)	0.63
Kawagishi et al. (2017) [72]	153	3	4 (2.6)	0.87
Ogawa et al. (2018) [78]	63	3	4 (6.3)	2.1
Tamori et al. (2018) [76]	765	3	1 (0.1)	0.33
Total	1317	3	12 (0.91)	0.61 (0–2.1)

HBsAg hepatitis B surface antigen, anti-HBc anti-hepatitis B core antibody, anti-HBs anti-hepatitis B surface antibody, EOT end of treatment, n number

^aThree patients (one with cirrhosis and two without cirrhosis) began anti-HBV treatment: one entecavir (ETV) and two tenofovir disoproxil fumarate (TDF)

^bThree patients (one with cirrhosis and two without cirrhosis) began TDF

^cOne cirrhotic patient began TDF

^dTwo patients, one had hepatic failure and one had icteric hepatitis

^eOne icteric patient began ETV